Trends in the management of alcohol withdrawal syndrome.
Alcohol use among head and neck cancer patients is common. Alcohol withdrawal (especially delirium tremens) poses significant potential morbidity to postsurgical patients. Treatment with newer benzodiazepines (BZDs) such as lorazepam and midazolam has become more widespread, and mortality rates from severe alcohol withdrawal have decreased in recent years. The authors retrospectively studied 102 patients with a diagnosis of alcohol withdrawal, including 20 patients undergoing surgery for cancer of the head and neck. There were 81 men and 21 women, with a mean (+/- standard deviation [SD]) age of 52.3 (+/- 16.1) years. Many of these patients (46%) were treated with more than one BZD or other neuroleptic, while 49% received single agent therapy of either chlordiazepoxide (26%) or lorazepam (23%). Delirium tremens occurred in 12% of all patients undergoing withdrawal and in 10% of head and neck cancer patients, with a mortality rate of 9% and 0%, respectively. Single agent use was successful in greater than 95% when either lorazepam or chlordiazepoxide was used. Instances of combination treatment where older BZDs were used yielded a 69% success rate. The higher complication rate and lower treatment success with combination treatment was multifactorial. Optimal management of the alcohol withdrawal syndrome requires an understanding of its pathophysiology and the principles of its prevention along with a familiarity of BZD pharmacokinetic drug profiles. The authors present a treatment plan which is cost-effective, keeps morbidity low, and should allow a continued decreasing trend in mortality rates from delirium tremens.
Division of Otolaryngology-Head and Neck Surgery, Stanford University Medical Center, CA 94305.
J P
JP
Newman
D J
DJ
Terris
M
M
Moore
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000430:Alcohol Withdrawal Delirium / Q000188:drug therapy; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002707:Chlordiazepoxide / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D002985:Clinical Protocols; D003975:Diazepam / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D004338:Drug Combinations; D000431:Ethanol / Q000009:adverse effects*; D005260:Female; D006258:Head and Neck Neoplasms / Q000601:surgery; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008874:Midazolam / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D004338:Drug Combinations; D000431:Ethanol; D002707:Chlordiazepoxide; D008140:Lorazepam; D003975:Diazepam; D008874:Midazolam